Search | Page 26 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Resistance to Hypomethylating Agents in the Treatment of MDS

    ... applies mostly to higher-risk MDS patients, because we don’t usually treat lower-risk category patients upfront with these agents. ... effect by inhibiting protein synthesis. Both drugs enter the cell and require a special enzyme to cause phosphorylation that results in its ...

    Interview last updated 06/17/2014 - 9:15am.

  2. Nonmyeloablative Haploidentical Transplant Followed by MLN9708

    ... strategies to augment the well documented effect of NK cell alloreactivity seen in HLA -mismatched transplantation. These ... receive a nonmyeloablative haploidentical transplant using a T-cell replete allograft and post-transplant cyclophosphamide as ...

    Clinical Trial last updated 04/29/2016 - 1:05pm.

  3. Conferences, Webinars and Webcasts

    ... -Judy  I now know this disease shouldn’t stop me from living life as best I can. – Evelyn   Webinars & ...   Caregivers   Clinical Trials   Stem Cell Transplantation   Living Well   Nutrition   ...

    Page last updated 09/30/2014 - 11:50am.

  4. Interviews with the Experts MDS Genomics: Providing ‘Street View’ Directions of Disease

    ... for any study of chromosomes , genes, and DNA in a cell. “Genetics” is a more specific term that pertains to the study of just ... There are situations where patients and doctors aren’t completely sure if the patient has MDS or not. The patient may have low blood ...

    Interview last updated 09/23/2014 - 9:30am.

  5. Allo HSCT Using RIC for Hematological Diseases

    ... followed by a related or unrelated donor stem cell infusion. The primary objective is to evaluate rates of acute ... include but are not limited to cytogenetics demonstrating t(9;22), t (1:19), t(4;11), other MLL rearrangements, hypodiploidy, or IKZF1 ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  6. Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

    ... the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with ... cells, and platelets. Giving an infusion of the donor's T cells (donor lymphocyte infusion) may help the patient's immune ...

    Clinical Trial last updated 04/29/2016 - 12:48pm.

  7. Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant

    ... Inclusion Criteria:  Age, Graft Cell Dose and Graft HLA Criteria Subjects must be <70 years old. ... Study of Infusion of Umbilical Cord Blood Derived CD25+CD4+ T-Regulatory (Treg) Cells after Non-Myeloablative Cord\Blood Transplantation ...

    Clinical Trial last updated 05/02/2016 - 2:13pm.

  8. Research Overview - Recent Past Progress and Projections for the Near-Term

    ... is that unlike solid tumors and leukemia, where there are cell lines that are propagated from the disease, we do not have reliable ... an enzyme called pyruvate dehydrogenase. This wasn’t just in MDS, but in all advanced hematologic malignancies. In this study, ...

    Interview last updated 02/10/2014 - 9:40am.

  9. HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

    ... to remove Tcells from blood stem cells . Removing T-cells may help stop a side effect called Graft-Versus-Host Disease (GVHD) ... correctable by transplant for which CD34+ selected, T-cell depleted allogeneic hematopoietic stem cell transplantation is indicated ...

    Clinical Trial last updated 04/29/2016 - 3:18pm.

  10. Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerou

    ... safety of nonmyeloablative conditioning and hematopoietic cell transplantation (HCT) from human leukocyte antigen ( HLA ... chimerism (> 5% cluster of differentiation [CD]3+ donor T-cell chimerism) in patients with nonmalignant inherited disorders. II. ...

    Clinical Trial last updated 04/26/2016 - 2:09pm.